REALTOX LABS LLC NPI 1235533779

NPI Details

REALTOX LABS, LLC is a clinical medical laboratory in Reisterstown, MD. The provider is (1) A clinical laboratory is a facility for the biological, microbiological, serological, chemical, immunohematological, hematological, biophysical, cytological, pathological, or other examination of materials derived from the human body for the purpose of providing information for the diagnosis, prevention, or treatment of any disease or impairment of, human beings. These examinations also include procedures to determine, measure, or otherwise describe the presence or absence of various substances or organisms in the body. Facilities only collecting or preparing specimens (or both) or only serving as a mailing service and not performing testing are not considered clinical laboratories. (2) Any facility that examines materials from the human body for purposes of providing information for the diagnosis, prevention, or treatment of any disease or impairment of, or the assessment of, the health of human beings. Typical divisions of a clinical laboratory include hematology, cytology, bacteriology, histology, biochemistry, medical toxicology, and serology. REALTOX LABS, LLC NPI is 1235533779. The provider is registered as an organization entity type.

The provider's business location address is:

200 BUSINESS CENTER DR
REISTERSTOWN, MD
ZIP 21136-230
Phone: (410) 833-3025
Fax: (410) 833-3158

The provider's authorized official is Joshua Gochnauer .
The authorized official title is Owner and has the following contact phone number (410) 833-3025.

The CLIA number assigned to this NPI record is 21D2077230 - independent with a certificate type of Certificate of Accreditation.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Detection test by nucleic acid for organism, amplified probe technique (HCPCS:87798)
• Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r (HCPCS:U0003)
• Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within (HCPCS:U0005)
• Detection test for candida species (yeast), amplified probe technique (HCPCS:87481)
• Evaluation of antimicrobial drug (antibiotic, antifungal, antiviral), microdilution or agar dilution (HCPCS:87186)
• Detection test by nucleic acid for organism, quantification (HCPCS:87799)
• Detection test by nucleic acid for strep (streptococcus, group b), amplified probe technique (HCPCS:87653)
• Detection test by nucleic acid for staphylococcus aureus (bacteria), amplified probe technique (HCPCS:87640)
• Detection test by nucleic acid for strep (streptococcus, group a), amplified probe technique (HCPCS:87651)
• Detection test by nucleic acid for cytomegalovirus, quantification (HCPCS:87497)
• Detection test by nucleic acid for strep (streptococcus, group a), quantification (HCPCS:87652)
• Detection test for candida species (yeast), quantification (HCPCS:87482)
• Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (HCPCS:G0483)
• Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (HCPCS:G0482)
• Detection test by multiplex amplified probe technique for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (covid-19), influenza virus types a and b, and respiratory syncytial virus (HCPCS:87637)
• Detection test by multiplex amplified probe technique for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (covid-19) and influenza virus types a and b (HCPCS:87636)
• Detection test by nucleic acid for herpes simplex virus, quantification (HCPCS:87530)
• Detection of mycoplasma genitalium by dna or rna probe (HCPCS:87563)
• Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (HCPCS:G0481)
• Detection test by nucleic acid for neisseria gonorrhoeae (gonorrhoeae bacteria), amplified probe technique (HCPCS:87591)
• Detection test by nucleic acid for chlamydia trachomatis, amplified probe technique (HCPCS:87491)
• Detection test by nucleic acid for chlamydia pneumoniae, amplified probe technique (HCPCS:87486)
• Detection test by nucleic acid for mycoplasma pneumoniae (bacteria), amplified probe technique (HCPCS:87581)
• Detection test by nucleic acid for trichomonas vaginalis (genital parasite), amplified probe technique (HCPCS:87661)
• Detection test by nucleic acid for neisseria gonorrhoeae (gonorrhoeae bacteria), quantification (HCPCS:87592)
• Detection test by nucleic acid for chlamydia trachomatis, quantification (HCPCS:87492)
• Measurement of dna of bacteria in vaginal fluid specimen (HCPCS:81514)
• Testing for presence of drug, by chemistry analyzers (HCPCS:80307)
• Detection test by nucleic acid for herpes simplex virus, amplified probe technique (HCPCS:87529)

The enumeration date for this NPI number is 10/13/2014 and was last updated on 10/13/2014.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.